6 completed, 1 recruiting. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Recruiting 1 |
| Phase 2 | 4 | Completed 3, Recruiting 1 |
Follow Diabetes Mellitus, Insulin-Dependent, 10: new trials by email Literature Review of Diabetes Mellitus, Insulin-Dependent, 10 trials Research Report on Diabetes Mellitus, Insulin-Dependent, 10
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer AU-007, Aldesleukin, Avelumab - Advanced Solid Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Recruiting | Aulos Bioscience, Inc. | 159 | 2022-04-04 | 2026-09-18 |
| Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis Daclizumab - Uveitis | Phase 2 | Completed | National Eye Institute (NEI) | 15 | 2002-08-01 | 2008-03-04 |
| Differences in Genes and Proteins in Active and Controlled Uveitis Ocular Inflammatory Disease, Uveitis | Completed | National Eye Institute (NEI) | 60 | 2002-02-01 | 2017-07-02 | |
| Anti-Tac for Treatment of Leukemia daclizumab - HTLV-I Infection, T Cell Leukemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 34 | 1999-12-01 | 2012-08-20 |
| HAT in Eye Complications of Behcet's Disease Daclizumab - Behcet's Syndrome, Retinal Disease | Phase 2 | Completed | National Eye Institute (NEI) | 26 | 1999-07-01 | 2008-03-04 |
| ANTI-TAC THERAPY FOR UVEITIS Daclizumab (Zenapax) - Uveitis | Phase 1 | Completed | National Eye Institute (NEI) | 15 | 1996-06-04 | 2017-07-02 |
| Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac Yttrium-90 radiolabeled anti-Tac antibody - Leukemia, T-Cell, Lymphoma, T-Cell, Cutaneous | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 1989-12-01 | 2008-03-04 |
Uveitis (4) · Leukemia, T-Cell (2) · Behcet Syndrome (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · HTLV-I Infections (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Melanoma (1) · Neoplasm Metastasis (1) · Retinal Diseases (1) · Retinal Vasculitis (1) · Squamous Cell Carcinoma of Head and Neck (1)
Eye Diseases (4) · Uveal Diseases (4) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Infections (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
Daclizumab (4) · Nivolumab (1) · aldesleukin (1) · avelumab (1)
National Eye Institute (NEI) (4) · National Cancer Institute (NCI) (2) · Aulos Bioscience, Inc. (1)
United States (7) · Australia (1)
James Vasselli, MD (1) · Thomas Waldmann, M.D. (1)